Puma Biotechnology News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.12.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.11.22	Puma Biotechnology Reports Third Quarter 2022 Financial Results (Businesswire)
02.11.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
27.10.22	Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium (Businesswire)
20.10.22	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)
04.10.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
20.09.22	Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor (Businesswire)
11.09.22	Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 (Businesswire)
06.09.22	Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference (Businesswire)
02.09.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.08.22	Puma Biotechnology Reports Second Quarter 2022 Financial Results (Businesswire)
21.07.22	Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results (Businesswire)
06.07.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.06.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.06.22	Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting (Businesswire)
04.06.22	Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting (Businesswire)
26.05.22	Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting (Businesswire)
11.05.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.05.22	Puma Biotechnology Reports First Quarter 2022 Financial Results (Businesswire)
27.04.22	Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting (Businesswire)
21.04.22	Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results (Businesswire)
05.04.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
10.03.22	Puma Biotechnology Announces $10 Million Private Placement (Businesswire)
07.03.22	Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference (Businesswire)
04.03.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.03.22	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Businesswire)
16.02.22	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
03.02.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
20.01.22	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
12.01.22	Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer (Businesswire)
10.01.22	Puma Biotechnology Releases Updated Corporate Presentation (Businesswire)
04.01.22	Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference (Businesswire)
10.12.21	Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting (Businesswire)
03.12.21	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
23.11.21	Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib) (Businesswire)
22.11.21	Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
20.11.21	Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting (Businesswire)
05.11.21	Pre-market Movers: RWLK, OTRK, EVAX, NRXP, PTON… (RTTNews)
02.07.21	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
01.07.21	FDA Approves Dose Escalation Label Update For Puma's NERLYNX In Metastatic Breast Cancer (RTTNews)
01.07.21	FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer (Businesswire)
19.05.21	Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting (Businesswire)
06.05.21	Puma Biotechnology Reports First Quarter 2021 Financial Results (Businesswire)
04.05.21	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
22.04.21	Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results (Businesswire)
13.04.21	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
17.03.21	CELC Inks Breast Cancer Trial Collaboration, CANF Soars On Deal With Ewopharma, MRUS On Watch (RTTNews)
08.03.21	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.03.21	Puma Biotechnology to Present at the Barclays Global Healthcare Conference (Businesswire)
02.03.21	Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Puma Biotechnology Inc

Aktien Top/Flop

Meistgelesene Nachrichten